MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas

• Published in: Radiology Vol. 190; no. 1; p. 269
• Main Authors: Sostman, H D, Prescott, D M, Dewhirst, M W, Dodge, R K, Thrall, D E, Page, R L, Tucker, J A, Harrelson, J M, Reece, G, Leopold, K A
• Format: Journal Article
• Language: English
• Published: United States 01-01-1994
• Subjects: Adult; Aged; Animals; Dog Diseases - diagnosis; Dog Diseases - therapy; Dogs; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prognosis; Sarcoma - diagnosis; Sarcoma - therapy; Sarcoma - veterinary; Soft Tissue Neoplasms - diagnosis; Soft Tissue Neoplasms - therapy; Soft Tissue Neoplasms - veterinary
• ISSN: 0033-8419
• DOI: 10.1148/radiology.190.1.8259418

To enable prediction of tumor response to a particular treatment.
The authors studied the value of hydrogen-1 T2 and phosphorus-31 magnetic resonance (MR) spectroscopic metabolic determinations as indicators of prognosis in 20 humans and 10 dogs with soft-tissue sarcomas. All patients underwent combined fractionated radiation therapy and hyperthermia. Surgical resection of the entire tumor in humans allowed comparison of pretherapy T2 and MR spectroscopic parameters with subsequent histologic findings. Long-term clinical follow-up (no surgical intervention) was available with the dogs and allowed comparison of pretherapy pH with the duration of local relapse-free survival.
A relationship exists between pretherapy pH and T2 and ultimate tumor necrosis in humans and pretherapy pH and time elapsed until local failure in dogs.
MR imaging and spectroscopy could be useful in the prognosis of patients with soft-tissue sarcomas before therapy is initiated.